ArticleScientific reports2025
Binding modes and interaction mechanism of bisphenol A and its analogs in constitutive androstane receptor.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Emerging insights of bile acids in cardiovascular physiology and disease: from molecular mechanisms to therapeutic potential.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Environmental pollutants, such as bisphenol A (BPA) and its analogs, are key molecules in the production of commercial products that are used in daily life, posing a threat to human health. BPA and its analogs modify the functional activity of nuclear receptors (NRs), acting as endocrine disruptors. The constitutive androstane receptor (CAR) is a nuclear hormone receptor that plays a critical role in xenobiotic metabolism, and bisphenols antagonize CAR activity. Although the binding mechanisms of BPA and its analogs to other NRs have been reported, the binding modes of bisphenols in CAR remain unclear. Therefore, in this study, we performed molecular docking to understand the binding modes and interaction patterns of BPA and its analogs with the CAR ligand-binding domain using an inverse agonist-bound structural conformation because bisphenols antagonize CAR functional activity. The complexes of the top-binding bisphenols were subjected to molecular dynamics simulations. BPA and its analogs showed strong binding affinities for CAR. However, the binding energy of BPA (−86.4 kJ/mol) was lower than that of its analogs (−94.13 to 141.2 kJ/mol). Hydrophobic and polar residues (Phe161, Asn165, Leu206, Phe217, Tyr224, Thr225, L246, I334, I337) in the binding pocket largely contribute to the binding energy. This study provides crucial information on the key residues of the CAR responsible for bisphenol binding, which may help design better therapeutics for CAR and bisphenol-associated diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.